|
|
 |
|
Viewing report
|
|
|
|
2006 Financings: IPOs and Pharmas Acquisitions of Private (IPO-less) Companies
Decision Resources, Inc, Dec 2006, Pages: 32
Private start-up life sciences companies use at least two different financing strategies: sell the whole company to a larger pharmaceutical company or sell shares of the company on a public market.
While these young companies may feel they are too young to die from an early acquisition, big pharma and private investors have a quite different perspective.
Get the Answers You Need to Shape Your Strategy
The market for acquiring private (IPO-less) companies is dynamic; on average, whole-company buyouts raise much more money than would an IPO. Pharma companies are cherry-picking the best product and company opportunities at an earlier and earlier stage of development.
Does the private company benefit from being bought out by a big pharma company? What are the benefits for big pharma?
Start-up life sciences companies dream of living long and prospering by developing new and improved medicines for the benefit of humankind, yet the IPO market is less than robust. Many private companies will be consumed by larger companies sooner than they might like.
Why is it so difficult for start-up companies to raise the funds they need to remain independent? Are there any options other than surrendering to a buyout?
Investments from 2006 public markets have not been all that satisfactory as financing vehicles for private companies or their investors. What deals took place so far in 2006 and how did the companies fare? Does the current state of the IPO market mean trouble for financing deals in the near future?
Investor exit strategies: overview of whole-company (IPO-less) buyout and IPO financing strategies.
Whole-company buyout strategy: benefi ts for large pharma companies and disadvantages for private companies.
IPO strategy: benefits for private companies and the current IPO market.
Select companies that completed IPOs in 2006: Acorda, Altus, BioMimetic, Cleveland BioLabs, Novacea, Omrix, Osiris, Vanda, Warner Chilcott.
Spectrum Expert Commentary: the view from an internationally known pharmaceutical consultant.
Outlook: overview of future financing opportunities for start-up companies.
|
|
|
|
